Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

The stock's fall snapped a two-day winning streak.

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...